LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases

21 hours ago 3

Maham Fatima

Wed, December 31, 2025 astatine 10:12 AM CST 2 min read

Prime Medicine Inc. (NASDAQ:PRME) is 1 of the best biotech penny stocks to bargain according to analysts. On December 23, LifeSci Capital initiated sum of Prime Medicine with an Outperform standing and $6 terms target. The steadfast highlighted that Prime Medicine is advancing one-and-done cistron editing treatments for conditions with precocious unmet aesculapian needs, specifically Wilson’s disease, alpha-1 antitrypsin deficiency/AATD, and cystic fibrosis. LifeSci Capital expressed peculiar optimism regarding the commercialized and objective opportunities Prime Medicine is pursuing wrong the Wilson’s illness and AATD landscapes

In different news, connected December 7, Prime Medicine Inc. (NASDAQ:PRME) announced the work of Phase 1/2 objective information for its investigational therapy, PM359, successful the New England Journal of Medicine/NEJM. PM359 is an autologous hematopoietic stem compartment merchandise designed to dainty p47phox chronic granulomatous disease/CGD. These findings correspond the first-in-human objection of Prime Editing’s information and efficacy.

LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential successful Liver and Lung Diseases

The proceedings results focused connected 2 patients, 1 big and 1 pediatric, some of whom had a past of CGD-defining complications, specified arsenic tegument infections and CGD-associated colitis. Following attraction with PM359, some patients achieved accelerated neutrophil and platelet engraftment. By Day 30, they reached 69% and 83% dihydrorhodamine-positive/DHR+ neutrophils, respectively. These figures importantly transcend the 20% threshold typically required for objective benefit. Because the DHR enactment remained unchangeable implicit time, researchers judge the cistron correction successfully occurred successful the semipermanent repopulating hematopoietic stem cells wrong the bony marrow. Clinically, some participants person remained escaped of caller CGD-related complications.

Prime Medicine Inc. (NASDAQ:PRME) is simply a biotechnology institution that delivers familial therapies to code the spectrum of diseases by deploying cistron editing exertion successful the US.

While we admit the imaginable of PRME arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.